| Jul 30 |
Evolus Q2 2024 Earnings Preview
|
| Jul 30 |
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia
|
| Jul 25 |
Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
|
| Jul 23 |
Evolus’s ‘frown line’ treatment Jeuveau could threaten Botox revenues
|
| Jul 17 |
Evolus to Report Second Quarter Financial Results on July 31, 2024
|
| Jul 1 |
Evolus Announces Appointment of Albert G. White III to Board of Directors
|
| Jun 24 |
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
|
| Jun 19 |
Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)
|
| Jun 12 |
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
|
| May 28 |
The Evolution of Medical Aesthetics and Its Growing Foothold in the Beauty Space
|
